Patents Examined by Fozia Hamud
  • Anti-CD123 antibodies and conjugates and derivatives thereof
    Patent number: 10077313
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: September 18, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel Tavares, Lingyun Rui, Thomas Chittenden
  • Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
    Patent number: 10066017
    Abstract: The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: September 4, 2018
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC
    Inventors: Leda Mannent, Gianluca Pirozzi, Brian Swanson, Allen Radin, Namita A. Gandhi, Robert Evans, Jennifer Hamilton
  • Therapeutic method of inducing mitochondrial biogenesis to treat skin and muscle pathologies
    Patent number: 10064919
    Abstract: A method of inducing mitochondrial biogenesis in a mammal is provided. The method comprises the step of administering to the mammal an interleukin-15 or nucleic acid encoding an interleukin-15 to the mammal.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 4, 2018
    Assignee: EXERKINE CORPORATION
    Inventors: Mark Tarnopolsky, Justin Crane
  • Compound targeting IL-23A and TNF-alpha and uses thereof
    Patent number: 10059763
    Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: August 28, 2018
    Assignees: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
    Inventors: Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
  • Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
    Patent number: 10053506
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: August 21, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
  • Muteins of tear lipocalin and methods for obtaining the same
    Patent number: 10046027
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: August 14, 2018
    Assignee: PIERIS PHARMACEUTICALS GMBH
    Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
  • Compositions and methods for preventing and treating infection
    Patent number: 10046030
    Abstract: The present invention encompasses compositions and methods useful to treat or prevent Clostridium difficile antibiotic-associated colitis through administration of IL-25 and/or downstream cytokines IL-13, IL-4, and IL-5. It is disclosed herein that IL-25 expression is decreased during antibiotic treatment and during bacterial infection and that treatment with IL-25 protein is protective during infection. It is further disclosed herein the unexpected result that IL-25 treatment protects against C. difficile-associated mortality and morbidity. The present application further describes an unexpected result regarding eosinophils and their role in combating infection and their relationship to the effectiveness of IL-25.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: August 14, 2018
    Assignee: University of Virginia Patent Foundation
    Inventors: William A. Petri, Jr., Erica Buonomo
  • Antagonists to IL-6 to raise albumin and/or lower CRP
    Patent number: 10040851
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: August 7, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • Microorganisms genetically engineered to have modified N-glycosylation activity
    Patent number: 10023854
    Abstract: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 17, 2018
    Assignees: Oxyrane UK Limited, VIB vzw, Universiteit Gent
    Inventors: Nico Luc Marc Callewaert, Wouter Vervecken, Karen Jacqueline Marcel De Pourcq, Steven Christian Jozef Geysens, Mouna Guerfal
  • Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection
    Patent number: 10017569
    Abstract: The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: July 10, 2018
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jordan Marshall Sand, Mark Eric Cook
  • IL-33 antagonists and uses thereof
    Patent number: 10011647
    Abstract: The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 3, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie M. Orengo
  • Method for treating a disease originated from receptor activation by EREG and TGF?
    Patent number: 10005832
    Abstract: The present inventors identified inhibition of a combination of EGFR ligands that serve as targets for inhibition of cancer cell proliferation. More specifically, EREG antagonists and TGF? antagonists were found to be useful as inhibitors of cell growth. The present invention relates to pharmaceutical compositions containing EGF family ligand antagonists as components.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 26, 2018
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenji Yoshida, Hirotaka Ito
  • Methods for determining risk of chronic lung allograft dysfunction (CLAD) and subtypes thereof
    Patent number: 10000809
    Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: June 19, 2018
    Assignee: University Health Network
    Inventors: Shaf Keshavjee, Mingyao Liu, Marcelo Cypel
  • Antagonists of IL-6 to raise albumin and/or lower CRP
    Patent number: 9994635
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: June 12, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • Use of IL-20 antagonists for treating pancreatic cancer
    Patent number: 9982043
    Abstract: Methods for treating pancreatic cancer using an IL-20 antagonist, which can be an antibody that binds IL-20 or an IL-20 receptor, thereby blocking the signaling pathway mediated by IL-20.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: May 29, 2018
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang
  • Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
    Patent number: 9981036
    Abstract: Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL 12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed. Method of modulating immune response and methods of inducing an immune response against an immunogen are disclosed. Therapeutic and prophylactic vaccination methods are also disclosed.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: May 29, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Matthew P. Morrow, Jian Yan
  • Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia
    Patent number: 9975937
    Abstract: The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: May 22, 2018
    Assignee: THE UNITED SSTATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: George N. Pavlakis, Barbara K. Felber, Antonio Valentin, Cristina Bergamaschi
  • Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13
    Patent number: 9957320
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing antibody molecules.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 1, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Anti-IL-6 antibodies for the treatment of oral mucositis
    Patent number: 9957321
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: May 1, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, Leon F. Garcia-Martinez, Andrew L. Feldhaus
  • Antagonists of IL-6 to raise albumin and/or lower CRP
    Patent number: 9957322
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: May 1, 2018
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith